Clinical trials: First Pregnancy
Cervical Cancer
A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
The study is being conducted to evaluate the efficacy, and safety of SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical…
- Trial name
- NCT05179239
- Testing
- SHR-1701 + paclitaxel + cisplatin/carboplatin + BP102, SHR-1701 + paclitaxel + cisplatin/carboplatin± BP102
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Cancer of Ovary, Pancreatic Ductal Adenocarcinoma
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
This multicenter Phase 2a study was designed to evaluate the safety, tolerability, and efficacy of Promitil in patients with recurrent ovarian cancer and inoperable, locally advanced or metastatic pancreatic cancer, which bears…
- Trial name
- NCT06478862
- Testing
- Promitil
- Where
- 6 sites in Israel
- Volunteers
- 19 people
- Sponsor
- Lipomedix Pharmaceuticals Inc.
Prematurity
Electrocardiography Versus Pulse Oximetry for Newborn Heart Rate Determination
The goal of this study is to compare the time required for accurate heart rate measurement of the preterm newborn when using pulse oximetry versus electrocardiography leads.
- Trial name
- NCT01256346
- Testing
- Apparatuses
- Where
- United States
- Sponsor
- University of Oklahoma
Post Date, Induction of Labor
Use of Single Versus Double Foley's Catheter in Pre-induction Cervical Ripening
Cervical ripening should be present before labor induction, which can generally be divided into two categories: pharmacological and mechanical
- Trial name
- NCT05511727
- Testing
- single versus double Foley's catheter in pre-induction cervical ripening
- Where
- Egypt
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
The NEO-811-101 study is an open-label, first-in-human, Phase 1/2 dose escalation and expansion study testing NEO-811, an ARNT molecular glue degrader, in subjects with locally advanced or metastatic non-resectable clear cell…
- Conditions
- Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
- Trial name
- NCT07300241
- Testing
- NEO-811
- Where
- 16 sites in United States
- Volunteers
- 30 people
- Sponsor
- Neomorph, Inc
Recurrent Spontaneous Abortion
Difference Between Mean Gestational Sac Diameter and Crown-rump Length as a Marker of First-trimester Pregnancy Outcome in Patients With Recurrent Spontaneous Abortion
Objective: To determine the effect and predictive value of the difference between the mean gestational diameter (mGSD) sac and crown-rump length (CRL) of the first trimester on the pregnancy outcomes of patients with recurrent…
- Trial name
- mGSD-CRL& RSA (NCT06081556)
- Testing
- ultrasonic testing
- Where
- China
- Volunteers
- 256 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Advanced or Recurrent Endometrial Cancer
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
This is a phase IIIb, interventional, single arm, multicentre study assessing the safety profile of durvalumab in combination with carboplatin-paclitaxel chemotherapy followed by durvalumab with olaparib as first-line treatment…
- Trial name
- DUoENDE (NCT06746116)
- Testing
- Durvalumab + Chemotherapy phase, Durvalumab + Olaparib phase
- Where
- 24 sites in Spain
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Fallopian Tube Cancer, Primary Peritoneal Cancer
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
The primary purpose of the study is to evaluate the efficacy of R-DXd with or without bevacizumab as maintenance therapy compared with standard of care (SOC) in participants with platinum-sensitive ovarian cancer (PSOC) as…
- Conditions
- Fallopian Tube Cancer, Primary Peritoneal Cancer, High-Grade Serous Ovarian Cancer, Endometrioid Epithelial Ovarian
- Trial name
- NCT07791732
- Testing
- R-DXd, Bevacizumab
- Volunteers
- 600 people
- Sponsor
- Daiichi Sankyo
Mental Disorders During Pregnancy
Efficacy and Feasibility of Baby Triple P - a Pilot Study
In the present pilot study the feasibility and efficacy of Baby Triple P- an antenatal parent training- are investigated. Healthy becoming first time parents were randomly allocated to either the Baby Triple P parent-training…
- Trial name
- NCT02313493
- Testing
- Baby Triple P
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Ruhr University of Bochum
Abortion in First Trimester
Progesterone and Doppler in Recurrent Abortion
Recurrent pregnancy loss is classically defined as the occurrence of three or more consecutive pregnancy loss. The American Society of Reproductive Medicine has recently redefined recurrent pregnancy loss as two or more pregnancy…
- Trial name
- NCT03267771
- Testing
- Progesterone Suppositories Vaginal, Dydrogesterone Oral Tablet, doppler ultrasound
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Urinary Incontinence, Overactive Bladder Syndrome
Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan
This clinical trial compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and antimuscarinics.
- Trial name
- NCT03059134
- Testing
- Mirabegron 25mg
- Volunteers
- 168 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
PR-0164 First in Human Clinical Trial of the PAVmed PortIO Intraosseous Infusion System
The PortIO is intended to provide non-emergent vascular access in chronic kidney disease (CKD) patients where preservation of venous anatomy is desired and iatrogenic damage to the veins should be avoided and/or patients with…
- Conditions
- Chronic Kidney Disease stage3, Chronic Kidney Disease stage4, Chronic Kidney Disease Stage 5, Poor Vascular Access
- Trial name
- NCT06037265
- Testing
- PAVmed PortIO™ Intraosseous Infusion System
- Where
- 4 sites in Colombia
- Volunteers
- 15 people
- Sponsor
- PAVmed Inc.
Kidney Failure, Chronic
Study to Compare Initial Dosing Parameters of Zemplar in Stage V Chronic Kidney Disease Subjects on Hemodialysis
To show non-inferiority in the incidence rates of elevated calcium-phosphorus product between two treatment groups: 1) a group having an initial dose based on baseline PTH (baseline iPTH/80) and 2) a group having a starting dose…
- Trial name
- NCT00091481
- Testing
- Zemplar
- Where
- 19 sites in Greece
- Volunteers
- 201 people
- Sponsor
- Abbott
Ovarian Carcinoma, Breast Carcinoma
Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer
This pilot clinical trial studies copper Cu 64-DOTA-B-Fab positron emission tomography (PET)/computed tomography (CT) in imaging patients with ovarian and breast cancer.
- Trial name
- NCT02708511
- Testing
- Computed Tomography, Copper Cu 64-DOTA B-Fab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Sanjiv Sam Gambhir
Cervical Cancer Recurrent or Persistent, Palliative Treatment
Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma
This study evauates the global survival of patients following administration of mAb Nimotuzumab hR3 + chemotherapy in the treatment of cervical cancer in first line therapy, after relapsing from chemo-radiotherapy.
- Conditions
- Cervical Cancer Recurrent or Persistent, Palliative Treatment, Monoclonal Antibody in Cervical Cancer Treatment
- Trial name
- NCT02083211
- Testing
- mAb Nimotuzumab
- Where
- Mexico
- Volunteers
- 168 people
- Sponsor
- National Institute of Cancerología
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00003944
- Testing
- filgrastim, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fox Chase Cancer Center
Labor Pain
Comparison of Dural Puncture Epidural Versus Conventional Epidural for Labour Analgesia in Primigravida
This study aims to compare the analgesic efficacy and safety of the Dural Puncture Epidural (DPE) technique versus the Conventional Epidural (CE) technique for labor analgesia in primigravida.
- Trial name
- NCT06766812
- Testing
- epidural set
- Volunteers
- 60 people
- Sponsor
- Sohag University
Ovulation Induction, Polycystic Ovary Syndrome
Myo-inositol Versus Clomiphene Citrate in PCOS
Specific aim: To compare inositol and the golden standard first line treatment of ovulation induction, namely clomiphene citrate.
- Conditions
- Ovulation Induction, Polycystic Ovary Syndrome, Clomiphene, Inositol
- Trial name
- NCT04306692
- Testing
- Myo-inositol, Clomiphene Citrate
- Where
- Belgium
- Volunteers
- 12 people
- Sponsor
- University Hospital, Ghent
Ovarian Cancer
A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer
Niraparib is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of ZL-2306 (Niraparib) for…
- Trial name
- NCT03709316
- Testing
- ZL-2306 (Nirapairb)
- Where
- 31 sites in China
- Volunteers
- 384 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Bladder Cancer
A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium
RATIONALE: Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether lapatinib ditosylate is more effective than a placebo in killing tumor cells.
- Trial name
- LaMB (NCT00949455)
- Testing
- lapatinib ditosylate
- Where
- 27 sites in United Kingdom
- Volunteers
- 204 people
- Sponsor
- Queen Mary University of London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.